NCT06299748 2026-02-17
A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.
argenx
Recruiting
Clinical Trials
1 trialsPolyradiculoneuropathy, Chronic Inflammatory Demyelinating × efgartigimod alfa × 90 days × Clear all